Ivor Elrifi Acquires 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock

Key Points

• CEO Ivor Elrifi bought 237,616 Tiziana Life Sciences shares at $1.00 each, increasing his direct ownership by 5.22% to 4.79 million shares. He also purchased 83,807 shares on August 4 and 667,000 shares on August 3.
• Tiziana shares rose 3.5% to $1.02, but remain below their 50-day and 200-day moving averages and within a 12-month range of $0.87 to $2.53.
• Analyst sentiment remains cautious: the stock has a consensus rating of “Reduce,” with one analyst rating it Hold and another rating it Sell.

Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) CEO Ivor Elrifi purchased 237,616 shares of the firm's stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $1.00 per share, with a total value of $237,616.00. Following the completion of the purchase, the chief executive officer directly owned 4,793,684 shares in the company, valued at approximately $4,793,684. This represents a 5.22% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Ivor Elrifi also recently made the following trade(s):

• On Tuesday, August 4th, Ivor Elrifi acquired 83,807 shares of Tiziana Life Sciences stock. The stock was acquired at an average cost of $0.97 per share, for a total transaction of $81,292.79.
• On Monday, August 3rd, Ivor Elrifi bought 667,000 shares of Tiziana Life Sciences stock. The shares were acquired at an average price of $1.00 per share, with a total value of $667,000.00.

Tiziana Life Sciences Stock Up 3.5%

TLSA stock traded up $0.04 during midday trading on Thursday, hitting $1.02. The company's stock had a trading volume of 434,962 shares, compared to its average volume of 240,434. Tiziana Life Sciences Ltd has a twelve month low of $0.87 and a twelve month high of $2.53. The company's fifty day moving average price is $1.15 and its 200 day moving average price is $1.30.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Wall Street Zen cut Tiziana Life Sciences from a "hold" rating to a "sell" rating in a research note on Saturday, April 18th. Zacks Research raised shares of Tiziana Life Sciences to a "hold" rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings downgraded shares of Tiziana Life Sciences from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, May 29th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Tiziana Life Sciences currently has a consensus rating of "Reduce".

Hedge Funds Weigh In On Tiziana Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bison Wealth LLC acquired a new position in Tiziana Life Sciences during the fourth quarter worth approximately $30,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Tiziana Life Sciences in the first quarter valued at approximately $25,000. Jane Street Group LLC boosted its stake in shares of Tiziana Life Sciences by 968.2% during the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock worth $181,000 after acquiring an additional 151,858 shares during the period. Marshall Wace LLP bought a new position in shares of Tiziana Life Sciences during the 2nd quarter worth approximately $39,000. Finally, Millennium Management LLC acquired a new position in shares of Tiziana Life Sciences during the 3rd quarter worth approximately $520,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc NASDAQ: TLSA is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company's lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source